We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

14 hedge funds and large institutions have $182K invested in Monopar Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

75% more funds holding

Funds holding: 8 → 14 (+6)

11% more capital invested

Capital invested by funds: $165K → $182K (+$17.7K)

0.13% more ownership

Funds ownership: 0.29% → 0.43% (+0.13%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 5

Holders
14
Holders Change
+6
Holders Change %
+75%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
–
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WAG
Windsor Advisory Group
Ohio
+$62.9K
2
TSS
Two Sigma Securities
New York
+$17.2K
3
HF
HRT Financial
New York
+$9.14K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.31K
5
FDCDDQ
Federation des caisses Desjardins du Quebec
Quebec, Canada
+$56

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$9.61K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$8.09K
3
Morgan Stanley
Morgan Stanley
New York
-$2.24K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$482
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$128
Name Holding Trade Value Shares
Change 		Change in
Stake
WAG
1
Windsor Advisory Group
Ohio
$55.8K +$62.9K +17,995 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$54.3K -$8.09K -2,316 -12%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$23.5K -$482 -138 -2%
TSS
4
Two Sigma Securities
New York
$15.3K +$17.2K +4,933 New
Millennium Management
5
Millennium Management
New York
$10.8K -$9.61K -2,750 -42%
HF
6
HRT Financial
New York
$7K +$9.14K +2,616 New
RRCM
7
Rappaport Reiches Capital Management
Illinois
$6.63K – – –
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$5.96K +$7.31K +2,092 New
TRCT
9
Tower Research Capital (TRC)
New York
$2.31K -$7 -2 -0.3%
Morgan Stanley
10
Morgan Stanley
New York
$496 -$2.24K -640 -80%
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Quebec, Canada
$50 +$56 +16 New
UBS Group
12
UBS Group
Switzerland
$45 +$49 +14 New
Wells Fargo
13
Wells Fargo
California
$20 – – –
JP Morgan Chase
14
JP Morgan Chase
New York
$2 +$3 +1 New
Fidelity Investments
15
Fidelity Investments
Massachusetts
– -$128 -30 Closed

MNPR Hedge Fund Activity: Q3 2023 in Review

14 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q3 2023, worth a combined $182K — up 11% from $165K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new MNPR positions and 1 closed out — a net gain of 6 holders — while 0 added to existing stakes and 5 trimmed.

The largest buyer was Windsor Advisory Group, opening a new position worth an estimated $62.9K. The largest seller was Millennium Management, cutting an estimated $9.61K.

  • 14 institutional investors held Monopar Therapeutics (MNPR) as of Q3 2023, up from 8 in Q2 2023.
  • Funds reported $182K of Monopar Therapeutics stock for Q3 2023, up 11% quarter-over-quarter.
  • 7 funds opened new Monopar Therapeutics positions in Q3 2023 and 1 closed out, a net change of +6 holders.
  • The largest Monopar Therapeutics buyer in Q3 2023 was Windsor Advisory Group, an estimated $62.9K added.
  • The largest Monopar Therapeutics seller in Q3 2023 was Millennium Management, an estimated $9.61K sold.

Based on aggregated 13F filings for Q3 2023.